Abiopharma

🔍 Gravier Pierre (Executive)

Company: PTC THERAPEUTICS, INC. (PTCT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 92,449.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 50,000 shares of Stock Option (Right to Buy) at $76.74 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
• F2: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.
• F3: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.